Xenetic Biosciences Inc. logo

Xenetic Biosciences (XBIO) stock

XBIO · Xenetic Biosciences Inc. · NASDAQ

Website
Market cap
$3.3M
EPS (TTM)
-$1.54
Shares out
2.3M

What is the latest news on XBIO stock?

SECago
SEC Form DEFA14A filed by Xenetic Biosciences Inc.

DEFA14A - Xenetic Biosciences, Inc. (0001534525) (Filer)

All XBIO news

When does Xenetic Biosciences report earnings?

The latest Xenetic Biosciences earnings release came out on Apr 27, 2022: Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities.

XBIO earnings history

Financial highlights

Full financials
Revenue, TTM
$2.96M
Revenue growth
+3.5%
Net income, TTM
-$3.66M
Net margin
-123.7%
Cash
$5.81M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

Latest news

25 items
News · 26 weeks15+500%
2026-05-24: 02026-05-31: 22026-06-07: 02026-06-14: 02026-06-21: 02026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 02026-07-26: 02026-08-02: 32026-08-09: 02026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 22026-09-20: 12026-09-27: 02026-10-04: 02026-10-11: 12026-10-18: 02026-10-25: 02026-11-01: 12026-11-08: 52026-11-15: 0
2026-05-242026-11-15
Mix1090d
  • SEC Filings5(50%)
  • Market4(40%)
  • 13D/G1(10%)
Activity · 52 weeks3522 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Xenetic Biosciences Inc. (XBIO) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for XBIO, including 3 SEC filings, 2 market updates and 1 13D/G filing. The most recent was published Nov 13, 2026.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

XBIO FAQ

8 questions
  • What does Xenetic Biosciences Inc. do?
    Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and...
  • What is XBIO revenue?
    Xenetic Biosciences Inc. (XBIO) reported $2.96M of revenue for the twelve months ended Sep 30, 2026. That is up 3.5% from the year before. Revenue for fiscal 2025 was $2.98M.
  • Is XBIO profitable?
    No. Xenetic Biosciences Inc. reported a net loss of $3.66M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does XBIO have?
    Xenetic Biosciences Inc. reported $5.81M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does XBIO stock trade?
    Xenetic Biosciences Inc. (XBIO) is listed on NASDAQ.
  • What sector and industry is XBIO in?
    Xenetic Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What companies are similar to XBIO?
    Notable peers in the same industry include IOVA (Iovance Biotherapeutics Inc.), LEGN (Legend Biotech Corporation), AUTL (Autolus Therapeutics plc). Compare XBIO side-by-side with any of them on Quantisnow.
  • How can I track XBIO on Quantisnow?
    Quantisnow aggregates Xenetic Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XBIO to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change